Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, Yoshino T, Yoshida K, Maehara Y.
Takahashi T, et al. Among authors: yamazaki k.
ESMO Open. 2021 Apr;6(2):100093. doi: 10.1016/j.esmoop.2021.100093. Epub 2021 Mar 19.
ESMO Open. 2021.
PMID: 33744811
Free PMC article.
Clinical Trial.